Anti-Ageing Therapies

Transcription

1 We were treated like royalty. Everything went very smoothly. The conference was a credit to the SMi team. Speaker, Pharmaceutical Conference, February 2002 Discover exciting new developments in Anti-Ageing Therapies 23rd & 24th October 2002, The Hatton, London A closer look at what we know about the ageing process and how it relates to age-associated diseases and their treatments Benefits of Attending UNDERSTAND the complexities of the ageing process KEEP UP TO DATE with the very latest developments in the treatment of ageing and age-related diseases, such as Alzheimer s disease, Parkinson s disease, dementia and cancer LEARN about the causes and effects of ageing in terms of identifying viable targets for new therapies E VA L U ATE the potential for developing therapeutics against ageing and responding to increasing consumer demand in an ageing population MEET key decision makers and make valuable industry contacts A unique opportunity to learn from leading industry experts including: Dr Jan Nehlin, Research Associate Professor, Novo Nordisk Dr Kenneth Sommerville, Neuroscience Medical Director, Abbott Laboratories Dr Stanley Shapiro, Vice President, Science and Technology, Johnson & Johnson Dr Bruce Gitter, Senior Research Scientist, Eli Lilly Charles Studer, Vice President, Novartis Foundation for Gerontology Dr Calvin Harley, Chief Scientific Officer, Geron Dr Bernard Malfroy-Camine, President & Chief Executive Officer, Eukarion PLUS A FULL DAY EXECUTIVE BRIEFING Genomics and Our Understanding of the Ageing Process 25th October 2002, The Hatton, London In association with: w w w. s m i - o n l i n e. c o. u k / a n t i a g e i n g. a s p Register online and receive full information on all of SMi s confere n c e s Or alternatively fax your re g i s t ration to +44 (0) Or call +44 (0) % DISCOUNT Academic Researchers receive 50% discount Supported by

2 w w w. s m i - o n l i n e. c o. u k / a n t i a g e i n g. a s p Register online and receive full information on all of SMi s confere n c e s Or alternatively fax your re g i s t ration to +44 (0) or call +44 (0) Registration & Coffee 9.00 Chairman's Opening Remarks Including a short talk on CARNOSINE PLURIPOTENCY AND ANTI-AGEING AGENTS Dr Alan Hipkiss, Senior Lecturer, Biochemistry, King s College London UNDERSTANDING THE AGEING PROCESS ANTI-AGEING THERAPEUTICS: AN INTRODUCTION 9.20 Strategic approaches to anti-ageing therapeutics Should one develop therapies for ageing or age-related diseases? Major proposed causes of ageing Summary of recent data supporting each cause of ageing Causes versus effects: does treating effects of ageing help? Therapies that address each proposed cause of ageing Best anti-ageing targets based on current data Dr Bryant Villeponteau, President & Chief Scientific Officer, HealthSpan Sciences ENDOCRINOLOGY OF AGEING 9.50 Disarray of endocrine systems in the ageing human Many hormones decline in their frequency, strength and production as we age What are the underlying mechanisms responsible? Relative magnitudes and time courses of different endocrine adaptations in the ageing human and in experimental animals The current focuses: HGH, DHEA, cortisol, melatonin, thyroid hormone and thymic hormones Targeting hormone precursors for anti-ageing therapies Implications of therapeutic reconstitution with hormones in the aged Dr Jan Nehlin, Scientist & Research Associate Professor, Novo Nordisk SLOWING DOWN AGEING FROM WITHIN Applying hormesis in biogerontology Gerontogenes Vitagenes Failure of maintenance Homeostasis and homeodynamics Stress response Healthy ageing Prof Suresh Rattan, Professor, Danish Centre for Molecular Gerontology, University of Aarhus Morning Coffee PHARMACOLOGICAL INTERVENTION AND TREATING THE AGEING DISORDER OXIDATIVE DAMAGE AND TARGETING ANTI-AGEING THERAPIES The fight against reactive oxygen species Understanding oxidative stress and its role in pathogenesis and ageing The anti-oxidant defence system Pharmacological intervention to counteract oxidative stress: synthetic catalytic scavengers Studies in animal models for diseases associated with ageing Clinical development programs Is oxidative stress one key to future research into ageing and age-related diseases? Dr Bernard Malfroy-Camine, President & Chief Executive Officer, Eukarion OXIDATIVE STRESS PROFILE Understanding the role of oxidative stress in the ageing process Longevity determinant genes and the dysdifferentiation hypothesis of ageing Evidence for primary ageing and primary anti-ageing processes The genetic complexity governing human ageing rate Oxidative stress represents a primary ageing process Processes governing oxidative stress status control stability of the differentiated cell Stability of the transcription/translation profile of cells govern whole organism ageing rate Determining the oxidative stress/antioxidant profile of patients Using the oxidative stress profile to create customised dietary supplements Demonstration that dietary supplements reduce patients oxidative stress status The Kronos Laboratory tests and optimum health program Dr Richard Cutler, Senior Scientist, Exeter Life Sciences/ Kronos Longevity Research Institute Networking Lunch MITOCHONDRIA AND LYSOSOMES IN PRIMARY MECHANISMS OF HUMAN AGEING 2.00 Developing drugs and gene therapies for post-mitotic cells Turnover of proteins and mitochondria in post-mitotic cells: decline with age Lipofuscin origins and consequences Mitochondrial DNA mutations take over cells Energy crisis and redox stress cause cell senescence and cell death Damage to the brain, heart and skeletal muscle Design of targeted therapies John Furber, Founder, Legendary Pharmaceuticals MITOCHONDRIAL DYSFUNCTION IN AGEING AND DISEASE 2.40 Novel polycyclic phenols as therapeutics Mitochondrial function and dysfunction in ageing Oxidative mitochondrial pathology and failure Mitochondrial contributions to disease (type 2 diabetes; Alzheimer s and Parkinson s diseases; glaucoma) Polycyclic phenols (PPCs) as drug development candidates Mechanisms of action and SAR Mitochondrial consequences of PPC treatment New directions and indications Dr James Dykens, Senior Scientist, Associate Director, Business & Corporate Development, Mitokor 3.20 Afternoon Tea DRUG TARGETING AND TELOMERASE 3.40 The telomere time keeper and the potential of telomerase for degenerative conditions of ageing Telomeres in the regulation of cellular senescence The shortening of telomeres appears to be the cellular clock that controls the ageing of our cells The telomere and telomerase connection Four approaches for killing telomerase-positive cells as cancer therapy Progress towards development of telomerase activators for degenerative conditions of ageing Dr Calvin Harley, Chief Scientific Officer, Geron THE CLOCK THAT WOULDN T BE BEATEN 4.20 Controlling the length of our telomeres An exclusive focus on developing therapeutics for treating ageing-related diseases Regulation of the human telomerase promotor to affect telomere length (the clock of ageing) Complete mutation map of the telomerase minimal promoter Strong repressor site identified Other telomerase gene regulatory elements identified Dr Bill Andrews, Founder & Vice President, Research, Sierra Sciences 5.00 Chairman s Closing Remarks and Close of Day One Supported by Pharma-i.com is the only community for the pharmaceutical, biotechnology, healthcare and related life sciences professional live on the Internet. This unique site features a rich mix of pharmaceutical industry news, drug research, clinical trial updates, product news, an events diary, the latest market research, discussion forums, e-commerce centres, and much more... Our 6,000 regular users include: Eli Lilly, Procter & Gamble, Novartis, Aventis, Pfizer, Parke-Davis, GSK, Merck & Co., Roche, Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, ICN Pharmaceuticals, Bayer, Solvay, Sanofi-Synthelabo, Ortho-McNeil, Yamanouchi, Byk Gulden, Rhone-Poulenc, Teva Pharmaceutical, Whitehall-Robins, Bayer, Servier Laboratories, Knoll, Janssen, Schering Health Care, Ipsen Limited, Du Pont Pharma, McNeil Consumer Healthcare, BioSante, and Genesis. Users include a wide range of senior executives in: clinical research, drug design, drug discovery, validation, lab equipment, compliance, quality assurance, regulation, licensing, drug delivery, gene therapy, biotechnology, pharmacoeconomics, bioinformatics, proteonomics, nutraceuticals, wholesale/distribution, sales/marketing, CROs, active ingredients, and medical devices. Want to know how you can get involved? Interested in promoting your pharmaceutical services to this market? Call Jacqueline Antill, SMi Marketing on +44 (0) or jantill@smi-online.co.uk Do you want to contact more than 25,000 key decision makers around the world with a targeted campaign? Target your marketing message directly to Clinical R&D Directors/Managers and their Teams. Please visit for more information. Complete the online form in the Marketing Services section to receive a detailed breakdown of the numbers available and a price for your send. Tel:+44 (0) , Fax: +44 (0) , info@drugdev123.com, Web:

3 w w w. s m i - o n l i n e. c o. u k / a n t i a g e i n g. a s p Register online and receive full information on all of SMi s confere n c e s Or alternatively fax your re g i s t ration to +44 (0) or call +44 (0) Re-registration & Coffee Networking Lunch 9.00 Chairman's Opening Remarks Dr Wilfried Bieger, Private Practice, ANT.OX THE AGEING BRAIN THE AGEING BRAIN AND ALZHEIMER S DISEASE 9.10 Brain dysfunction affecting the lives of millions as they grow old: a closer look at Alzheimer s Alzheimer s disease: the most common cause of dementia among older people Using in vitro cell and transgenic animal models to investigate the amyloid hypothesis of Alzheimer s disease pathogenesis Understanding the role of amyloid precursor protein (APP) processing enzymes in the production, deposition and clearance of brain Aß deposits Alternative strategies to reduce brain Aß deposits and reverse cognitive deficits in transgenic animal models of APP over expression Dr Bruce Gitter, Senior Research Scientist, Eli Lilly OXIGON TM : DUAL MECHANISM APPROACH TO THE TREATMENT OF ALZHEIMER S DISEASE 9.40 Targeting the beta-amyloid cascade in Alzheimer s disease The central role of beta-amyloid cascade in AD Oxidative stress in AD Therapeutic strategies for AD Complexities of trial design in AD: symptomatic versus disease modifying therapies OXIGON TM : a potent neuroprotective molecule Prof Paul Bendheim, Executive Vice President & Chief Medical Officer, Mindset BioPharmaceuticals A PROMISING ANTI-AMYLOID APPROACH TO ALZHEIMER S DISEASE THERAPY Gag mimetics Glycosaminoglycans (GAGs) promote amyloid formation GAG mimetics bind to amyloid protein and block amyloid formation in animal model of AD GAG mimetics reduce brain inflammation associated with amyloid deposits GAG mimetics: an oral drug candidate with a promising safety profile in clinical phase I trials Dr Francine Gervais, Vice President, Research & Development, Neurochem Morning Coffee BRAIN AGEING AND GLUTAMATE Positive modulation of glutamatergic transmission: a promising therapeutic target Glutamate: the primary neurotransmitter in the mammalian brain for excitatory communication AMPA receptor activity: its significance for cognitive function How much potentiation is enough: how much is too much? Ampakines: increased neutrophin (BDNF and NGF) expression to slow brain ageing Ampalex: the effects of CX516 in the elderly with mild cognitive impairment Dr Gary Rogers, Senior Vice President, Pharmaceutical Research, Cortex Pharmaceuticals DIVALPROEX (DEPAKOTE) IN DEMENTIA Clinical data and future directions Divalproex has shown effectiveness in treating agitation in dementia in clinical trials Divalproex dosing needs to be followed carefully in the elderly with dementia Divalproex may have properties to slow the progression Future directions in research with divalproex in dementia Dr Kenneth Sommerville, Neuroscience Medical Director, Abbott Laboratories THE AGEING SKIN AGEING SKIN 2.00 Dermatological care to reverse skin damage Signs of ageing primarily caused by photo damage How does our skin change: the dangers of skin immunosuppression Synthetic phenolic hormones with anti-inflammatory and immunostimulatory properties Topical application: the potential for protection against UV-induced skin damage and as an anti-ageing formulation So called anti-ageing creams that temporarily moisturise the skin but do not reverse damage Case study: NV-07a: the ability to undo skin damage following UV exposure Prof Alan Husband, Research Director, Novogen NEW TECHNOLOGICAL SOLUTIONS TO YOUNGER SKIN 2.40 Case study: Renova The quest for young looking skin: the need for medical intervention The look good generation and tapping into the cosmeceutical market Intrinsic and extrinsic factors responsible for skin ageing Common active ingredients to defy signs of ageing ReNova as a skin rejuvenation treatment Dr Stanley Shapiro, Vice President, Science and Technology, Johnson & Johnson 3.20 Afternoon Tea GENE AND CELL THERAPIES FOR AGE-RELATED DISEASES CELL THERAPY FOR AGE-RELATED DISEASES 3.40 Gene and cell therapy for age-related disease Stem cells Cell replacement Host vs. graft reaction Safety Functionality Regulatory hurdles Dr Don Kleinsek, Chief Executive Officer, GeriGene Medical A LOOK AT HOW ANTI-AGEING THERAPIES AND LIFESTYLE CHANGES CAN BE INTEGRATED ANTI-AGEING AND HEALTH EDUCATION 4.20 Using pharmacological therapies in conjunction with lifestyle changes Ageing is risky Major risk factors in an ageing population The role of education and informing the older person Experience with health promotion on the internet Working towards a healthier old age: how can we combine anti-ageing drugs and lifestyle changes to maximise quality of life for the elderly? Charles Studer, Vice President, Novartis Foundation for Gerontology 5.00 Chairman's Closing Remarks and Close of Conference SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Jackie McDonald, SMi Sponsorship on +44 (0) or jmcdonald@smi-online.co.uk

4 PHARMACEUTICAL FORWARD PLANNER MAY /30 Advances in hypertension and cardiovascular therapeutics JUNE /11 Pain Therapeutics 17/18 Therapeutic Antibodies 26/27 Neurodegenerative Disorders SEPTEMBER /24 Commercial Issues in Drug Delivery 30/1 Oct Clinical Trials & Data Management OCTOBER /03 Signal Transduction Therapeutics 09/10 Pharmacogenomics 14/15 From Hit to Lead Optimising Drug Development 16/17 Prevention & Treatment of Allergy 21/22 Pricing & Reimbursement in the Pharmaceutical Industry 23/24 Anti-Ageing Therapies 28/29 Diabetes NOVEMBER /07 Clinical Trials in CNS 18/19 Wholesale Distribution in the Pharmaceutical Industry 18/19 Tissue Engineering 20/21 Blood & Drugs DECEMBER /03 Vaccines 04/05 Dermatology

5 Genomics and Our Understanding of the Ageing Process 25th October 2002, The Hatton, London In association with: This briefing will take a look at the curre n t theories on why we age and how we can determine the way in which ageing is dictated by our genetic code. In a series of discussion sessions, the briefing will evaluate how we can go about i n c reasing our knowledge of the genomics of ageing and longevity and the problems that may be encountered along the way Registration & Coffee 9.00 Genomics and ageing: an overview Theories of ageing Model systems Morning Coffee Age-related changes in gene expression Transcriptional analysis of gene expression Proteomic approaches to ageing Lunch 2.00 Genomic approaches to human longevity Difficulties with studying ageing in humans Identification of longevity loci 3.45 Afternoon Tea 4.00 Bringing it together: a system s approach to ageing Synthesis of data from diverse sources Developing a molecular mechanism of ageing 5.15 Discussion and questions: review of session 5.30 Close of Briefing About your briefing leader Dr Matt Kaeberlein is a recognised authority in the field of ageing and longevity research. He has done extensive analyses of the molecular mechanisms of ageing and longevity in various biological systems and is an author of numerous scientific articles in the field. He is an advisor and database curator for the Science of Aging Knowledge Environment. As Vice President of Research at Longenity, Dr Kaeberlein is leading the scientific team in their work to discover treatments for age-associated diseases and disorders. About the company Longenity is a biotechnology company using genomics, bioinformatics, and systems biology to understand the ageing process in humans. Our goal is to develop treatments that slow ageing and remediate the symptoms associated with old age.

6 REGISTRATION FORM Conference: 23rd & 24th October 2002 Executive Briefing: 25th October % DISCOUNT Academic Researchers will receive 50% discount on marked price Proof of status to be sent with registration Unique Reference Code Your purchase order no PLEASE USE BLOCK PRINT - PLEASE COMPLETE FORM IN FULL T i t l e F o re n a m e I n i t i a l s S u r n a m e D e p a r t m e n t Job Title O rg a n i s a t i o n A d d ress To w n / C i t y C o u n t y Post/Zip code C o u n t r y D i rect Phone D i rect Fax S w i t c h b o a rd Phone S w i t c h b o a rd Fax E m a i l Booking Contact Job Title Immediate Manager Business Sector Number of employees on site Signature I agree to SMi Conferences Ltd Terms and Conditions of Booking. Please register the following delegates for (photocopy for multiple registrations) Anti-Ageing Therapies 23rd 25th October 2002, The Hatton, London Date I cannot attend the conference but wish to purchase: 300 Documentation (including postage and packing) 500 Documentation and Audio Tapes (including VAT, postage and packaging) To order, complete the Registration Form and complete your method of payment. Payment must be received before the goods can be despatched which will be 7-14 days after the conference. PAYMENT: I enclose a cheque (drawn on a UK Bank made payable to SMi Conferences Ltd) I am transferring the money to HSBC Bank plc, Account No: , Sort Code: (For overseas customers please use SWIFT CODE MIDLGB22) 28 Borough High Street, London SE1 1YB Please debit my credit card (including % & tax) Visa/MasterCard (1.90%) Amex (3.80%) Diners (3.00%) Eurocard (1.90%) Card No Expiry Date Signature Date I agree to SMi Conferences Ltd Terms and Conditions of booking and SMi debiting my credit card. EXECUTIVE PACKAGES For our Executive package inclusive of a discount of 100, tick below: Option A Conference & Executive Briefing Fee: VAT: Total: Tick here for either the conference or executive briefing but not both: Option B Conference only Fee: VAT: Total: Option C Executive Briefing only Fee: VAT: Total: ACADEMIC DISCOUNT Option D Conference only Fee: VAT: Total: How to register: By mail: Complete and return your signed Registration Form together with your cheque to: SMi Conferences Ltd, 1 New Concordia Wharf, Mill St, London SE1 2BB By fax: Complete and fax your signed Registration Form with your credit card details to +44 (0) By internet: Complete your Registration Form online with your credit card details at How to contact us: Telephone: +44 (0) Fax: +44 (0) customer_services@smi-online.co.uk Web: How we will contact you: SMi Conferences Ltd s preferred method of communication is by and phone. Please ensure you complete the Registration Form so that we can contact you. We will use postal services on a request basis only. Venue: The Hatton, Hatton Garden, London EC1N 8HN. The Hatton is SMi Conferences Ltd s bespoke state of the art conference venue and has excellent transport links to all London airports, with train and tube stations nearby. There are also three NCP car parks in close proximity. Full details will be included in your conference joining pack. We can arrange your travel, accommodation, transfers and insurance. The SMi JVT team are available to make your journey and stay during the conference as hassle free and as smooth as possible. SMi JVT can book your accommodation, flights, transfers and arrange insurance all at the best possible rate. Please contact us on +44 (0) fax +44 (0) travel@smi-online.co.uk or visit our website Please book early to get the full advantage of our travel packages. Payment terms: SMi Conferences Ltd require the full amount to be settled prior to the event taking place. SMi Conferences Ltd reserves the right to refuse entry to any customer who has not paid their invoice. A credit card guarantee may be requested if full payment has not been received. Methods of payment: Payment must be in sterling. You can pay by cheque drawn on a UK bank, payable to SMi Conferences Ltd or by bank transfer to HSBC Account No: Sort Code: (For overseas customers please use SWIFTCODE MIDLGB22) 28 Borough High St, London SE1 1YB, or by credit card. Please complete the Registration Form. When making payments please quote delegate s name and conference and/or product. Interest: SMi Conferences Ltd reserves the right to charge interest on any unpaid invoices. SPONSORSHIP OPPORTUNITIES Jackie McDonald, SMi Sponsorship on +44 (0) or jmcdonald@smi-online.co.uk MARKETING OPPORTUNITIES Jacqueline Antill, SMi Marketing on +44 (0) or jantill@smi-online.co.uk Alteration to invoices: Any alterations to an invoice, excluding substitutions/names changes, requested by the customer will incur an administration fee of 50 and will be charged to the customer by credit card prior to the amendment being made. Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post, fax, or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes which are available on the day will be sent to you. Unfortunately we are not able to transfer places between conferences and conferences and workshops. However, if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by , fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries. Indemnity: SMi Conferences Ltd reserve the right to change the conference/workshop content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of SMi Conferences Ltd. If such a situation arises we will endeavour to reschedule the event. However, SMi Conferences Ltd cannot be held responsible for any cost, damage or expenses which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses. SMi JVT can provide this insurance. Data Protection: SMi Conferences Ltd (part of the SMi Group Ltd) gathers data in accordance with the UK Data Protection Act The information about you contained on this form may be used to update you on SMi Group products and services via post, telephone, fax or , unless you state that you do not want us to do so. We may also share your data with other companies within the SMi Group, or external companies offering complementary products or services. If you do not wish for your details to be passed on to any external third party, or if you have any queries regarding the data we hold on you, please contact our Database Manager (databasemanager@smionline.co.uk) SMi Information Services Ltd (part of the SMi Group Ltd), 1 New Concordia Wharf, Mill St, London, SE1 2BB, United Kingdom. The fee includes lunch, refreshments and conference papers provided on the day. It does not include travel, hotel accommodation, transfers or insurance (which we strongly recommend you obtain). VAT will be charged at the local rate on each conference. Delegates may be able to recover VAT incurred by contacting Eurocash Corporation plc (0) , eurocash@eurocashvat.com. Eurocash are specialists in recovering cross border VAT. If you have NOT received re g i s t ration confirmation within 48 hours of registering, please call +44 (0)